| Author/Editor | Savšek, Lina | |
| Title | Zdravljenje multiple skleroze z monoklonskimi protitelesi: obvladovanje tveganj | |
| Translated title | Monoclonal antibodies in multiple sclerosis: risk management | |
| Type | članek | |
| Source | In: [Zbornik prispevkov] Ljubljana : Medicinski razgledi | |
| Publication year | 2021 | |
| Volume | str. 5-10 | |
| Language | slv | |
| Abstract | Monoklonska protitelesa igrajo vse bolj pomembno vlogo pri zdravljenju bolnikov z multiplo sklerozo. Svojo visoko učinkovitost dosežejo s ciljanjem specifičnih tarč celic imunskega sistema, ki igrajo ključno vlogo v patogenezi multiple skleroze. Zaradi specifičnega načina delovanja povzročajo manj interakcij z drugimi zdravili, kar zmanjšuje pojavnost stranskih učinkov. Kljub temu pa zaradi delovanja na imunski sistem zdravljenje z monoklonskimi protitelesi lahko sproži pojav okužb, malignosti, avtoimunih obolenj ali tvorbo protiteles, ki zmanjšajo učinkovitost zdravila. Ob vnosu lahko pride do infuzijskih ali alergijskih reakcij. Ta tveganja lahko pomembno zmanjšamo z ustrezno izbiro zdravila glede na profil bolnika ter s skrbno predpripravo in nadaljnjim spremljanjem. Namen prispevka je predstaviti načine delovanja in profil stranskih učinkov trenutno registriranih monoklonskih protiteles ter načine obvladovanja tveganja, ki ga nosi takšno zdravljenje, vključno s priporočili za cepljenje proti nalezljivim boleznim in priporočili za zdravljenje v primeru načrtovanja družine.Monoclonal antibodies are quickly becoming a mainstay in treatment of patients with multiple sclerosis. Their high efficacy is acheived through targeting the immune system which plays a key role in the patogenesis of multiple sclerosis. Because of their specificity, they have less drug-drug interactions which minimizes the occurence of side effects. However, the occurence of various infections, new autoimmune or malignant diseases or neutralizing antibodies which limit the treatment efficacy can all be triggered by their specific effect on the immune system and their administration can cause infusion related reactions. By proper patient selection and preparation and careful monitoring during therapy we can minimize the occurence of these potentially serious side effects. This article provides an overview of currently available monoclonal antibodies, including their mechanism of action and side effect profiles. Furthermore, practical recommendations for treatment de-risking, along with recommendations about vaccinations and family planning, are provided. | |
| Descriptors | Multiple sclerosis Monoclonal antibodies Multipla skleroza Monoklonska protitelesa Drug therapy Therapeutic use terapija z zdravili terapevtska raba |